PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Gesamtlänge aller Episoden: 11 days 12 hours 51 minutes
Expert Advice on Uncontrolled Asthma: Should I Consider a Biologic for This Patient?
Expert Advice on Uncontrolled Asthma: Should I Consider a Biologic for This Patient?
Practice Challenges in Advanced EGFR-Mutant NSCLC: Clarifying First-Line Strategies
Practice Challenges in Advanced EGFR-Mutant NSCLC: Clarifying First-Line Strategies
A Case in Point: Navigating the Differential Diagnosis of aHUS in Clinical Practice
A Case in Point: Navigating the Differential Diagnosis of aHUS in Clinical Practice
Breaking the Cycle of Severe Hypoglycemia in Diabetes: Educating Clinicians and Patients Alike
Breaking the Cycle of Severe Hypoglycemia in Diabetes: Educating Clinicians and Patients Alike
Transforming Management of Early-Stage EGFR-Mutant NSCLC: Insights From the Latest Data
Transforming Management of Early-Stage EGFR-Mutant NSCLC: Insights From the Latest Data
Extending Overall Survival in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) While Maintaining Quality of Life: Can We Have it All?
Extending Overall Survival in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) While Maintaining Quality of Life: Can We Have it All?
Defining Control in Moderate-to-Severe Asthma: Where Are We Now and What Can We Do?
Defining Control in Moderate-to-Severe Asthma: Where Are We Now and What Can We Do?
Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy
Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy
Best Practices for MET Mutation Testing in NSCLC: The Role of the Oncologist and the Pathologist
Best Practices for MET Mutation Testing in NSCLC: The Role of the Oncologist and the Pathologist